Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.45 USD
Change Today +0.20 / 1.16%
Volume 794.0K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Halozyme Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Revenues for the first quarter of 2015 were $18.7 million, compared to $12.0 million for the first quarter of 2014. Revenues in the first quarter included $6.8 million in royalty revenue from sales of products under collaboration agreements, $6.1 million in product sales of bulk rHuPH20 for use in manufacturing collaboration products for Roche, $3.8 million in Hylenex recombinant (hyaluronidase human injection) product sales, and $2.0 million in collaboration revenues. The net loss for the first quarter of 2015 was $15.1 million, or $0.12 per basic and diluted share, compared to a net loss for the first quarter of 2014 of $26.5 million, or $0.22 per basic and diluted share. Operating loss was $13,911,000 compared to $25,219,000 a year ago. The company provided earnings guidance for the full year of 2015. For the full year 2015, the company reiterated its previously disclosed guidance of net revenues to be in the range of $85 million to $95 million. Net cash burn to be between $35 million to $45 million.

Halozyme Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM

Halozyme Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: David A. Ramsay, Chief Financial Officer and Vice President.

Halozyme Therapeutics, Inc. to Report Q1, 2015 Results on May 11, 2015

Halozyme Therapeutics, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 11, 2015

Halozyme Therapeutics, Inc., Q1 2015 Earnings Call, May 11, 2015

Halozyme Therapeutics, Inc., Q1 2015 Earnings Call, May 11, 2015

Halozyme Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-18-2015 02:00 PM

Halozyme Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-18-2015 02:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Helen I. Torley, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $17.45 USD +0.20

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $14.80 USD +0.13
Valeant Pharmaceuticals International Inc C$291.64 CAD 0.00
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.7x
Price/Book 58.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.